NephroPOC - Risk assessment and prediction of acute kidney injury in emergency patients with suspected organ dysfunction: Secondary analysis from the prospective observational LifePOC study

We aimed to assess markers and risk factors for imminent acute kidney injury (AKI) in emergency patients, as risk stratification in the emergency department is currently not widely used. Using data from a sub-cohort (440 patients) of the prospective multicentre LifePOC study (1434 patients), proenkephalin A 119-159 (penKid) was assessed for early identification of subclinical kidney damage compared to serum creatinine in emergency patients with a qSOFA score ≥1. Logistic regression was applied to assess the usefulness of penKid, four further biomarkers (midregional pro-adrenomedullin, bioactive adrenomedullin, dipeptidyl-peptidase-3, procalcitonin) and clinical risk factors to predict AKI within 24 h, 48 h and 72 h after admission, need for organ support and 28-day mortality. PenKid and bio-adrenomedullin performed moderately to predict AKI within 48 h (AUC 0.645, 95% CI: 0.582-0.703 and AUC 0.647, 95% CI: 0.583-0.707, respectively). Pre-existing chronic kidney disease (OR 2.36, 95% CI: 1.06-5.27), confirmed sepsis (OR 2.41, 95% CI: 1.28-4.56), mechanical ventilation (OR 3.03, 95% CI: 1.48-6.19), and elevated levels of penKid (OR 2.21, 95% CI: 1.60-3.07) at admission were associated with an increased risk of AKI whereas a restrictive fluid management (OR 0.43, 95% CI: 0.26-0.71) was associated with a lower risk of AKI. Patients at high AKI risk may be identified based on specific risk factors, bio-ADM and penKid. The trial was registered in the German Registry for Clinical Trials (DRKS00011188) on 20 October 2016.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-02-18
DOI
https://doi.org/10.1371/journal.pone.0339763
Primary Topic
Acute Kidney Injury Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

NephroPOC - Risk assessment and prediction of acute kidney injury in emergency patients with suspected organ dysfunction: Secondary analysis from the prospective observational LifePOC study

Margit Leitner, Myrto Bolanaki, Caroline Neumann, Anna Slagman et al.
PLoS ONE
Acute Kidney Injury Research
article

NephroPOC - Risk assessment and prediction of acute kidney injury in emergency patients with suspected organ dysfunction: Secondary analysis from the prospective observational LifePOC study

Margit Leitner, Myrto Bolanaki, Caroline Neumann, Anna Slagman, Martin Möckel, Thomas Lehmann, Johannes Winning, Michael Kiehntopf, Michael Joannidis, Michael Bauer
article en

Abstract

We aimed to assess markers and risk factors for imminent acute kidney injury (AKI) in emergency patients, as risk stratification in the emergency department is currently not widely used. Using data from a sub-cohort (440 patients) of the prospective multicentre LifePOC study (1434 patients), proenkephalin A 119-159 (penKid) was assessed for early identification of subclinical kidney damage compared to serum creatinine in emergency patients with a qSOFA score ≥1. Logistic regression was applied to assess the usefulness of penKid, four further biomarkers (midregional pro-adrenomedullin, bioactive adrenomedullin, dipeptidyl-peptidase-3, procalcitonin) and clinical risk factors to predict AKI within 24 h, 48 h and 72 h after admission, need for organ support and 28-day mortality. PenKid and bio-adrenomedullin performed moderately to predict AKI within 48 h (AUC 0.645, 95% CI: 0.582-0.703 and AUC 0.647, 95% CI: 0.583-0.707, respectively). Pre-existing chronic kidney disease (OR 2.36, 95% CI: 1.06-5.27), confirmed sepsis (OR 2.41, 95% CI: 1.28-4.56), mechanical ventilation (OR 3.03, 95% CI: 1.48-6.19), and elevated levels of penKid (OR 2.21, 95% CI: 1.60-3.07) at admission were associated with an increased risk of AKI whereas a restrictive fluid management (OR 0.43, 95% CI: 0.26-0.71) was associated with a lower risk of AKI. Patients at high AKI risk may be identified based on specific risk factors, bio-ADM and penKid. The trial was registered in the German Registry for Clinical Trials (DRKS00011188) on 20 October 2016.

PLoS ONEVol. 21(2)
Carl Zeiss (Germany) (DE), Innsbruck Medical University (AT), Humboldt-Universität zu Berlin (DE), Jena University Hospital (DE)
Openalex Percentile: Top 58%
Acute Kidney Injury Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.